Shortages of essential cancer medicines have a direct impact on patient care across Europe. To ensure that this issue remains a top priority on the EU policy agenda, the European Society for Medical Oncology (ESMO)…

European Society for Medical Oncology (ESMO), Munich (Germany) – Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval…

Amsterdam, The Netherlands. Cancer patients are living longer and in many cases the disease is becoming chronic rather than acute. Access to drugs that help extend life and improve quality of life, and fair prices…